Answers are grounded in this paper and cite their sources.
Evaluates adverse drug reactions of botulinum toxin-A, indicating the need for enhanced safety measures.
Background Despite the increasing use of botulinum toxin type A (BoNT‐A) in aesthetic and therapeutic applications, its real‐world adverse drug reaction (ADR) profile remains incompletely characterized. Current evidence relies largely on small‐scale clinical observations rather than large, systematic analyses. Objective To evaluate ADRs associated with BoNT‐A using pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) database (2004–2025). Methods We analyzed 155 449 BoNT‐A‐related ADR reports from the FAERS database after deduplication and data cleaning. Disproportionality analyses were conducted using four established algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi‐item gamma Poisson shrinker (MGPS). We evaluated time‐to‐onset and system organ class (SOC) distributions and identified high‐risk ADR signals. Results A biphasic pattern of ADR onset was observed, with an initial peak within 30 days after injection and a second, smaller peak beyond the 360‐day mark. The most frequently reported SOCs were general disorders and administration‐site conditions (33.22%); injury, poisoning, and procedural complications (16.81%); and nervous system disorders (11.16%). Eyebrow ptosis, botulism, blepharoptosis, facial paresis, and reuse of single‐use products were identified as strong safety signals. Females accounted for 87.8% of reported cases, and the 18–64.9 years age group was the most affected. Conclusion BoNT‐A is associated with a broad ADR profile spanning multiple organ systems, with identifiable temporal patterns. These findings highlight the importance of injection technique, dose control, and patient monitoring, particularly during both early and late post‐treatment phases. Enhanced pharmacovigilance and targeted risk management strategies are needed to improve patient safety in clinical practice.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: